These results strongly indicate that doxycycline directly targets PAR1 to suppress tumor progression in a dose-dependent manner, and these results provide an explanation as to why doxycycline exerts anti-vascular effects, which includes the inhibition of MMPs. This evidence concerns the gene F2R and neoplasm.